New drug YOLT-202 tested in early trial for rare lung and liver disease

NCT ID NCT07193615

Ongoing Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study is testing a single dose of a new drug called YOLT-202 in 18 adults with Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can damage the lungs and liver. The main goal is to see if the drug is safe and to find the best dose. Participants will receive one intravenous infusion and be monitored for side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YOLT-202 (a single-dose intravenous drug)
What this could lead to: If it works, this could point toward a new treatment option for people with Alpha-1 antitrypsin deficiency, a genetic lung and liver condition.
What could go wrong: This is a very early, small study with only 18 participants. It is designed mainly to check safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alpha 1-antitrypsin deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)

Contacts and locations

Locations

Ren Ji Hospital Affiliated to Shanghai Jiao Tong University

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.